A phase 3 trial of upadacitinib for giant-cell arteritis
https://www.coltonconsortium.org/publications/a-phase-3-trial-of-upadacitinib-for-giant-cell-arteritis/
Archives: “Archives”
Showing 231 - 240 of 265 posts
A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe granulomatosis with polyangiitis
https://www.coltonconsortium.org/publications/a-randomized-double-blind-placebo-controlled-trial-of-abatacept-for-the-treatment-of-relapsing-non-severe-granulomatosis-with-polyangiitis/
A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients
https://www.coltonconsortium.org/publications/a-retrospective-evaluation-of-glucagon-like-peptide-1-receptor-agonists-in-systemic-lupus-erythematosus-patients/
Agent-based modeling for personalized prediction of an experimental immune response to immunotherapeutic antibodies
https://www.coltonconsortium.org/publications/agent-based-modeling-for-personalized-prediction-of-an-experimental-immune-response-to-immunotherapeutic-antibodies/
An autoimmune transcriptional circuit drives FOXP3+ regulatory T cell dysfunction
https://www.coltonconsortium.org/publications/an-autoimmune-transcriptional-circuit-drives-foxp3-regulatory-t-cell-dysfunction/
Assessment of damage in Takayasu’s arteritis
https://www.coltonconsortium.org/publications/assessment-of-damage-in-takayasus-arteritis/
Association of autoantibody concentrations and trajectories with lupus nephritis histologic features and treatment response
https://www.coltonconsortium.org/publications/association-of-autoantibody-concentrations-and-trajectories-with-lupus-nephritis-histologic-features-and-treatment-response/
Yale News Spotlights the Colton Center as a Key Driver of Autoimmune Innovation at Yale Ventures
https://www.coltonconsortium.org/news/yale-news-spotlights-the-colton-center-as-a-key-driver-of-autoimmune-innovation-at-yale-ventures/A Yale News feature on Yale Ventures' five accelerator funds highlights the Colton Center for Autoimmunity's growing role in translating autoimmune research into startups, licenses, and real-world therapies.
Yale Researchers Use Machine Learning Tool to Improve Personalized Immunotherapy Design
https://www.coltonconsortium.org/news/yale-researchers-use-machine-learning-to-improve-personalized-cancer-vaccine-design/A Colton-supported Yale study has produced ImmunoStruct, a machine learning model that improves personalized cancer vaccine design by incorporating the 3D structure of immune-activating peptides — now licensed to a Yale spinout.
Yale Study Discovers a Second Pathway for Gut Antibody Production — With Implications for Vaccine Design
https://www.coltonconsortium.org/news/yale-study-discovers-a-second-pathway-for-gut-antibody-production-with-implications-for-vaccine-design/A Colton-supported Yale study has uncovered a second pathway for gut IgA antibody production, revealing a built-in immune backup system with significant implications for mucosal vaccine design.